A five-amino-acid peptide blocks Met- and Ron-dependent cell migration

Cancer Research

Volumn 65, Issue 14, 2005, Pages 6105-6110

  Matzke, Alexandra ^a   Herrlich, Peter ^a,b   Ponta, Helmut ^a   Orian Rousseau, Véronique ^a  

^a KARLSRUHE INSTITUTE OF TECHNOLOGY   (Germany)

^b FRITZ LIPMANN INSTITUTE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; HERMES ANTIGEN; ISOPROTEIN; PEPTIDE; PROTEIN TYROSINE KINASE; RECEPTOR; RON PROTEIN; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL CELL; ARTICLE; BINDING COMPETITION; CANCER; CELL MIGRATION; CONTROLLED STUDY; ENZYME ACTIVATION; EXON; HUMAN; HUMAN CELL; LIGAND BINDING; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT;

AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, CD44; CELL MOVEMENT; GLYCOPROTEINS; HT29 CELLS; HUMANS; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; PROTO-ONCOGENE PROTEINS; RATS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, GROWTH FACTOR; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 22244454747     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-0207     Document Type: Article

References (26)

1. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003;4:915-25.
2. Huff JL, Jelinek MA, Borgman CA, Lansing TJ, Parsons JT. The protooncogene c-sea encodes a transmembrane protein-tyrosine kinase related to the Met/ hepatocyte growth factor/scatter factor receptor. Proc Natl Acad Sci U S A 1993;90:6140-4.
3. Ronsin C, Muscatelli F, Mattel MG, Breathnach R. A novel putative receptor protein tyrosine kinase of the met family. Oncogene 1993;8:1195-202.
4. Medico E, Mongiovi AM, Huff J, et al. The tyrosine kinase receptors Ron and Sea control "scattering" and morphogenesis of liver progenitor cells in vitro. Mol Biol Cell 1996;7:495-504.
5. Chen YQ, Zhou YQ, Angeloni D, Kurtz AL, Qiang XZ, Wang MH. Overexpression and activation of the RON receptor tyrosine kinase in a panel of human colorectal carcinoma cell lines. Exp Cell Res 2000;261:229-38.
6. Danilkovitch-Miagkova A. Oncogenic signaling pathways activated by RON receptor tyrosine kinase. Curr Cancer Drug Targets 2003;3:31-40.
7. Giordano S, Corso S, Conrotto P, et al. The semaphorin 4D receptor controls invasive growth by coupling with Met. Nat Cell Biol 2002;4:720-4.
8. Orian-Rousseau V, Chen L, Sleeman JP, Herrlich P, Ponta H. CD44 is required for two consecutive steps in HGF/c-Met signaling. Genes Dev 2002;16:3074-86.
9. Conrotto P, Corso S, Gamberini S, Comoglio PM, Giordano S. Interplay between scatter factor receptors and B plexins controls invasive growth. Oncogene 2004;23:5131-7.
10. Günthert U, Hofmann M, Rudy W, et al. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 1991;65:13-24.
11. Rudy W, Hofmann M, Schwartz-Albiez R, et al. The two major CD44 proteins expressed on a metastatic rat tumor cell line are derived from different splice variants: each one individually suffices to confer metastatic behavior. Cancer Res 1993;53:1262-8.
12. Herrlich P, Zoller M, Pals ST, Ponta H. CD44 splice variants: metastases meet lymphocytes. Immunol Today 1993;14:395-9.
13. Lamb RF, Hennigan RF, Turnbull K, et al. AP-1-mediated invasion requires increased expression of the hyaluronan receptor CD44. Mol Cell Biol 1997;17:963-76.
14. Matzku S, Komitowski D, Mildenberger M, Zoller M. Characterization of BSp73, a spontaneous rat tumor and its in vivo selected variants showing different metastasizing capacities. Invasion Metastasis 1983;3:109-23.
15. Morgenstern JP, Land H. A series of mammalian expression vectors and characterisation of their expression of a reporter gene in stably and transiently transfected cells. Nucleic Acids Res 1990;18:1068.
16. Sleeman J, Kondo K, Moll J, Ponta H, Herrlich P. Variant exons v6 and v7 together expand the repertoire of glycosaminogiycans bound by CD44. J Biol Chem 1997;272:31837-44.
17. de Belder AN, Wik KO. Preparation and properties of fluorescein-labelled hyaluronate. Carbohydr Res 1975;44:251-7.
18. Sleeman JP, Arming S, Moll JF, et al, Hyaluronate-independent metastatic behavior of CD44 variant-expressing pancreatic carcinoma cells. Cancer Res 1996;56:3134-41.
19. Matzku S, Wenzel A, Liu S, Zoller M. Antigenic differences between metastatic and nonmetastatic BSp73 rat tumor variants characterized by monoclonal antibodies. Cancer Res 1989;49:1294-9.
20. Khaldoyanidi S, Karakhanova S, Sleeman J, Herrlich P, Ponta H. CD44 variant-specific antibodies trigger hemopoiesis by selective release of cytokines from bone marrow macrophages. Blood 2002;99:3955-61.
21. Sleeman J, Rudy W, Hofmann M, Moll J, Herrlich P, Ponta H. Regulated clustering of variant CD44 proteins increases their hyaluronate binding capacity. J Cell Biol 1996;135:1139-50.
22. Hofmann M, Rudy W, Zoller M, et al. CD44 splice variants confer metastatic behavior in rats: homologous sequences are expressed in human tumor cell lines. Cancer Res 1991;51:5292-7.
23. Follenzi A, Bakovic S, Gual P, Stella MC, Longati P, Comoglio PM. Cross-talk between the proto-oncogenes Met and Ron. Oncogene 2000;19:3041-9.
24. Jiang WG, Lloyds D, Puntis MC, Nakamura T, Hallett MB. Regulation of spreading and growth of colon cancer cells by hepatocyte growth factor. Clin Exp Metastasis 1993;11:235-42.
25. Tanimura S, Chatani Y, Hoshino R, et al. Activation of the 41/43 kDa mitogen-activated protein kinase signaling pathway is required for hepatocyte growth factor-induced cell scattering. Oncogene 1998;17:57-65.
26. Ruoslahti E. RGD and other recognition sequences for integrins. Annu Rev Cell Dev Biol 1996;12:697-715.